Martin Gosling

Prof Martin Gosling has spent his research career exploiting the therapeutic potential of ion channels in both industrial and academic settings. Prior to co-founding Enterprise Therapeutics, Prof Gosling was Executive Director in the Respiratory Disease Area of the Novartis Institutes for BioMedical Research, UK. Whilst with Novartis he established an internal ion channel platform, was a successful Project Team Leader for multiple drug discovery programs and played a lead role in defining the Novartis cystic fibrosis (CF) portfolio. Prof Gosling holds a BSc and PhD in Pharmacology from the Universities of Leeds and Aston respectively. In addition to his position as CSO of Enterprise Therapeutics, he also holds the position of Professor of Molecular Pharmacology at the University of Sussex.